Bunning R A, Haworth S L, Cooper E H
J Urol. 1979 May;121(5):624-5. doi: 10.1016/s0022-5347(17)56910-4.
Serum beta-2-microglobulin levels were measured in patients with renal, vesical and prostatic cancer. Measurements were made only on samples with a serum creatinine less than or equal to 105 mumol./l. to eliminate the possibility of elevated beta-2-microglobulin being a result of impaired renal function. This criterion eliminated 28 to 50 per cent of the patients with bladder cancer and 73 per cent of those who had undergone nephrectomy for renal carcinoma, which, obviously, limits the value of beta-2-microglobulin measurement for the surveillance in these cancers. Beta-2-microglobulin values in patients with prostatic cancer were seldom increased to more than 3.0 mg./l. In bladder cancer patients with normal serum creatinine the frequency of an elevated serum beta-2-microglobulin increased with the increase in tumor stage.
对患有肾癌、膀胱癌和前列腺癌的患者测量了血清β2-微球蛋白水平。仅对血清肌酐小于或等于105μmol/l的样本进行测量，以排除β2-微球蛋白升高是肾功能受损所致的可能性。该标准排除了28%至50%的膀胱癌患者以及73%因肾癌接受肾切除术的患者，显然，这限制了β2-微球蛋白测量在这些癌症监测中的价值。前列腺癌患者的β2-微球蛋白值很少升高到超过3.0mg/l。在血清肌酐正常的膀胱癌患者中，血清β2-微球蛋白升高的频率随肿瘤分期的增加而增加。
